In contrast, real‐world data have demonstrated that switching to degludec from other basal insulins, including glargine U100, under conditions of routine clinical care, results in significant improvements in glycaemic control alongside other clinical benefits for T1D or T2D.29 By using treat‐to‐target data from a clinical trial setting, the present analysis may, therefore, underestimate the clinical benefits of degludec experienced in the real‐world clinical setting. The gene discussed is INS; the disease is type 1 diabetes mellitus.